Irvine, Calif. (ots-PRNewswire) - Edwards Lifesciences Corporation
(NYSE: EW) announced today that it has completed the sale of its
Bentley line of cardiopulmonary products (also called "perfusion
products") to Jostra AG for approximately $30 million.
"This transaction represents a positive outcome for our two
companies, as well as for customers and employees of the Bentley line
of perfusion products," said Michael A . Mussallem, Edwards' chairman
and CEO. "Edwards has been working very aggressively to focus our
product portfolio and affect our transformation following the
company's spin-off from Baxter International earlier this year. This
transaction continues our progress and enables us to devote even more
of our energy to pursuing future growth opportunities."
Under terms of the agreement, Jostra, a leading European
manufacturer of medical devices for open-heart surgery based in
Hirrlingen, Germany, has acquired most of the assets associated with
Bentley perfusion products, which are based primarily in the United
States, Puerto Rico and Western Europe. Jostra will continue to make
available the full line of Bentley products, which are used to
support the heart during stopped-heart cardiac surgery, and include
disposable oxygenators, blood reservoirs, and filters, as well as
hardware and related products. Jostra also assumes responsibility for
Edwards' perfusion products manufacturing operations in Anasco,
Edwards retains its Macchi line of cardiopulmonary products, as
well as its manufacturing facilities in Sao Paulo, Brazil and Uden,
The Netherlands. Edwards also maintains distribution rights for
Bentley products in Japan and most other countries outside of the
U.S. and Western Europe. In addition, the agreement calls for Edwards
to provide transition support to Jostra.
Additional terms of the agreement enable Jostra to maintain
Bentley's role as a preferred supplier to Edwards' worldwide
perfusion services operations. Edwards is the world's leading
supplier of trained clinicians, capital equipment and disposable
supplies for open-heart surgery.
Edwards Lifesciences designs, develops and markets a comprehensive
line of products and services to treat late-stage cardiovascular
disease. Headquartered in Irvine, Calif., Edwards focuses on cardiac
surgery, critical care, vascular systems and perfusion products and
services, and is a worldwide leader in tissue replacement heart
valves and heart valve repair products. Additional information about
Edwards Lifesciences can be found at www.edwards.com.
This news release includes forward-looking statements that involve
risks and uncertainties, including those related to targeted
financial and operating objectives, technological advances in the
medical field, product demand and market acceptance, and other risks
detailed in the company's filings with the Securities and Exchange
Commission. These forward-looking statements are based on estimates
and assumptions made by management of the company and are believed to
be reasonable, though are inherently uncertain and difficult to
predict. Actual results or experience could differ materially from
the forward-looking statements.
Macchi is a trademark of Edwards Lifesciences Corporation.
ots Original Text Service: Edwards Lifesciences Corporation
Investors, David K. Erickson, (USA) 949-250-6826, or
Media, Scott Nelson, (USA) 949-250-5070,
both of Edwards Lifesciences Corporation
Web site: http://www.edwards.com Original-Content von: Edwards Lifesciences Corporation, übermittelt durch news aktuell